ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 423

Cardiovascular Risk and Lipid Screening in Rheumatoid Arthritis Patients in a University Rheumatology Practice: Quality Improvement Project

Diana Mosteanu, Xuan Wang, Donald Kimpel and Janet Lewis, University of Virginia, Charlottesville, VA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Quality Measures and Quality of Care - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Meta-analyses of observational studies showed that RA patients’ morbidity and mortality risks stemming from cardiovascular (CV) causes were, respectively, close to 50% and 60% higher than those of the general population. It has been proposed that high-grade inflammation affects multiple tissues and leads to endothelial dysfunction, dyslipidemia, more oxidative stress, increased levels of homocysteine, and insulin resistance. These effects accelerate atherogenesis and myocardial microvascular abnormalities. Research has shown that the tools used for risk assessment in the general population underestimate the true risk when they are applied to patients with proatherogenic diseases such as diabetes mellitus (DM) or chronic kidney disease (CKD). Evidence suggests that this is also the case with RA.

Methods: We reviewed the electronic medical records (EMR) of patients with the diagnosis of RA based on the ICD 9 codes, that were followed at the University of Virginia Rheumatology outpatient clinic in the 7/2014 – 5/2015 period. We reviewed age, gender, RF/CCP positivity, disease duration of more than 10 years, current smoking status, systolic blood pressure (SBP) and treatment, lipid panel (date, total cholesterol, HDL, LDL), cholesterol medications, DM status, aspirin use. We calculated the cardiovascular risk by multiplying the Framingham risk score by 1.5 as per EULAR recommendations.

Results: A total of 460 charts were reviewed. 78% of patients were female and 22% were male. 44.56% had lipid levels available in the EMR. Of the patients with documented lipid levels 49.75% had levels checked more than 2 years ago. Only 22.39% of the total patients reviewed had recent lipid levels documented in the EMR (less than 2 years old). Of the 359 female patients, 28.91% were on cholesterol medications although 60.84% had an LDL level greater than 100. 15.32% were smokers, 14.2% had a diagnosis of DM, while 29.24% had an SBP of more than 140. Of the 101 male patients, 56.41% were on cholesterol medications and 43.58% had an LDL level greater than 100. 22.77% were smokers, 19.8% had a diagnosis of DM, and 29.7% had an SBP of more than 140. Our data for female patients shows that the Framingham risk score is higher than the average population in all age groups except for the 55 – 64 years old age group and significantly higher in all age groups when multiplied by 1.5. Our data for male patients shows that the Framingham risk score is higher than the average population in all age groups except for the 60-69 years old age group and significantly higher in all age groups when multiplied by 1.5.

Conclusion: Studies have shown that RA patients have an increased cardiovascular risk, similar to DM and CKD population and twice as high as the general population. Our chart review shows that our RA patients have a number of CV risk factors and have an increased risk compared to the normal population based on calculated Framingham risk score as well as multiplication for RA. Additionally it appears that lipid screening and aggressive treatment for hypertension is underutilized in this population. We propose to send letters to the primary care practitioners to increase awareness of the CV risk assessment in RA.


Disclosure: D. Mosteanu, None; X. Wang, None; D. Kimpel, None; J. Lewis, None.

To cite this abstract in AMA style:

Mosteanu D, Wang X, Kimpel D, Lewis J. Cardiovascular Risk and Lipid Screening in Rheumatoid Arthritis Patients in a University Rheumatology Practice: Quality Improvement Project [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-risk-and-lipid-screening-in-rheumatoid-arthritis-patients-in-a-university-rheumatology-practice-quality-improvement-project/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-and-lipid-screening-in-rheumatoid-arthritis-patients-in-a-university-rheumatology-practice-quality-improvement-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology